ExpreS2ion Biotechnologies will provide the Protein Purification Facility at Cancer Research UK’s London Research Institute with access to its Drosophila Schneider-2 cell-based technology platform—ExpreS2—for protein production as part of a research license agreement. The nonlytic, fully cGMP compatible protein expression platform will be used to address expression of complex and “challenging” proteins, including Fab fragments and other proteins.
ExpreS2ion says this license is a relevant addition to its vision of making its production platform available to academic centers of excellence globally, plus it complements the company's goal of making S2 one of the standard protein production platforms in the immunotherapy and therapeutic protein segments.
“We have in the past used the ExpreS2 protein expression system to enable the advance of cancer projects, and this research license confirms the relevance of the system in complementing existing protein needs in cancer research,” Charlotte Dyring, Ph.D., CEO of ExpreS2ion Biotechnologies, said.
The institute sounds enthusiastic, too: “We are very pleased with the capabilities demonstrated by the ExpreS2 platform, which we have employed for a number of our taxing projects,” Svend Kjaer, Ph.D., head of the Protein Purification Facility at the London Research Institute, commented. “The technology complements our baculovirus-based protein expression activities perfectly, and we look forward to expanding the application range of the technology to other projects involving other promising protein targets implicated in cancer.”